AC
PRQR icon

Apogem Capital’s ProQR Therapeutics PRQR Stock Holding History

Apogem Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-124,424
Closed -$93K – 95
2022
Q3 		$93K Sell
124,424
-849
-0.7% -$682 0.09% 130
2022
Q2 		$97K Buy
125,273
+81,373
+185% +$60.7K 0.09% 148
2022
Q1 		$40K Buy
43,900
+17,025
+63% +$57K 0.03% 172
2021
Q4 		$215K Buy
26,875
+5,045
+23% +$38.4K 0.14% 157
2021
Q3 		$183K Sell
21,830
-10,207
-32% -$66.7K 0.12% 177
2021
Q2 		$216K Sell
32,037
-2,617
-8% -$16.9K 0.14% 162
2021
Q1 		$229K Buy
34,654
+18,799
+119% +$96.1K 0.16% 148
2020
Q4 		$67K Buy
+15,855
New +$66.9K 0.04% 158

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Apogem Capital's PRQR Position: Q4 2022 in Review

Apogem Capital sold out of ProQR Therapeutics (PRQR) in Q4 2022, closing a stake of 124,424 shares — an estimated $93K sold.

Apogem Capital first reported a position in PRQR in Q4 2020 and held it in 8 quarters. The position peaked at $229K in Q1 2021. 46 funds tracked by Wall St. Rank hold PRQR as of Q4 2022.

  • Apogem Capital reported no remaining ProQR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 124,424 ProQR Therapeutics shares in Q4 2022, an estimated $93K.
  • Apogem Capital first reported a position in ProQR Therapeutics in Q4 2020 and held it in 8 quarters.
  • Apogem Capital's ProQR Therapeutics position peaked at $229K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.